March 9, 2021 -- Taysha Gene Therapies has established a multiyear collaboration with a team of Yale University researchers. The goal is to advance next-generation minigene payloads for adeno-associated viral (AAV) gene therapies for the treatment of neurodevelopmental disorders.
This collaboration follows the company's previously announced collaborations with the Cleveland Clinic and University of Texas Southwestern Gene Therapy Program (UTSW) to support the creation of a novel next-generation minigene platform designed to overcome key challenges in gene therapy.
The current collaboration is with Dr. Yong-Hui Jiang, PhD, professor and chief of medical genetics at Yale University. The team of Yale University researchers will create minigene payloads to treat neurodevelopmental disorders, including intellectual disability. Also, UTSW will produce viral vector constructs that incorporate the minigene payloads and evaluate the constructs for in vivo and in vitro efficacy.
As part of the collaboration, Taysha will have an exclusive option on new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under the agreement.